In Brief: Furoscix - A Subcutaneous Furosemide Infusor for Heart Failure
The Medical Letter on Drugs and Therapeutics · 2023
DOI: 10.58347/tml.2023.1668d ↗Kurz gefasst
Fachartikel in der Zeitschrift The Medical Letter on Drugs and Therapeutics, 2023. Hauptthemen laut MEDLINE: Furosemide, Heart Failure. Die Arbeit wurde bisher 2-mal zitiert (Crossref).
Themen: Herzinsuffizienz
Abstract (Originalsprache)
The FDA has approved Furoscix (scPharmaceuticals), a subcutaneous formulation of the loop diuretic furosemide administered via a single-use, on-body infusor, for treatment of congestion due to fluid overload in adults with New York Heart Association (NYHA) Class II-III chronic heart failure (HF). Furosemide (Lasix, and generics) has been available for years in oral and IV formulations.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Zitieren
APA
(2023). In Brief: Furoscix - A Subcutaneous Furosemide Infusor for Heart Failure. The Medical Letter on Drugs and Therapeutics. https://doi.org/10.58347/tml.2023.1668d
Vancouver
In Brief: Furoscix - A Subcutaneous Furosemide Infusor for Heart Failure. The Medical Letter on Drugs and Therapeutics. 2023. doi:10.58347/tml.2023.1668d
BibTeX
@article{euvimed2023,
title = {In Brief: Furoscix - A Subcutaneous Furosemide Infusor for Heart Failure},
journal = {The Medical Letter on Drugs and Therapeutics},
year = {2023},
doi = {10.58347/tml.2023.1668d}
}
EUVIMED